Children

A liquid formulation of fosamprenavir was approved in the United States and European Union in 2007 for use in patients aged two to 18. In the US, use of fosamprenavir is approved for use in children two years and older. Dosing is adjusted based on age, weight, and antiretroviral experience. Check national guidelines or the manufacturer's website for dosing tables.

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.